Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients - A systematic review and network meta-analysis

SGLT2 inhibitors followed by GLP-1 RA provide strong benefits for CV and kidney health in patients with T2DM and CKD. SGLT2 inhibitors demonstrate superior benefit over GLP-1 receptor agonists for HF and renal outcomes, highlighting their preferred role in these clinical scenarios.